In this study, the immuno-response of recombinant hCG-β and natural hCGβ was comparatively investigated by using Freund's adjuvant. The results showed that, the properties and merits of the antibodies elicited b...In this study, the immuno-response of recombinant hCG-β and natural hCGβ was comparatively investigated by using Freund's adjuvant. The results showed that, the properties and merits of the antibodies elicited by both kinds of hCG-β were similar. The antisera had high affinity for binding with hCG (Kαγβ≈5.86×108/mol/L, Kαβ≈8.18×108/mol/L), and were found to be effective in inhibiting the binding of 125I-hCG to receptors in rat testes. Results also indicated that, similar to the antisera induced by natural hCG-β, the recombinant hCG-β induced antisera had capacity of neutralizing the biological activities of hCG. Recombinant hCG-β could be used as an immunogen for contraceptive vaccine.展开更多
目的评价中孕期母血清甲胎蛋白(alpha-fetoprotein,AFP)和游离人绒毛膜促性腺激素β亚基(freeβsubunit of human chorionic gonadotropin,freeβ-HCG)二联法产前筛查胎儿染色体非整倍体异常的效果。方法采用多中心回顾性研究方法,分析2...目的评价中孕期母血清甲胎蛋白(alpha-fetoprotein,AFP)和游离人绒毛膜促性腺激素β亚基(freeβsubunit of human chorionic gonadotropin,freeβ-HCG)二联法产前筛查胎儿染色体非整倍体异常的效果。方法采用多中心回顾性研究方法,分析2007年10月至2014年9月,在杭州市五家产前筛查中心自愿接受产前筛查的437 438例孕妇的出生缺陷监测资料及杭州市各区、县妇幼保健院上报的产前筛查随访结果资料。评估唐氏综合征(Down′s Syndrome,DS)的风险值。结果筛查高风险孕妇中确诊DS胎儿130例、18三体综合征37例、其他非整倍体异常11例;在随访的筛查低风险孕妇中确诊新生儿DS 52例、18三体综合征9例、其他非整倍体异常7例。二联法产前筛查的灵敏度分别为71.43%(130/182)、80.43%(37/46)、61.11%(11/18);假阳性率分别为3.21%(14 050/437 256)、0.14%(609/437 392)、3.39%(14 815/437 420);筛查结果为高风险的孕妇,其检出DS、18三体综合征、其他非整倍体异常胎儿的概率高于低风险者,两者差异均有统计学意义(P<0.01)。结论血清学AFP、freeβ-HCG二联产前筛查不仅能筛查DS、18三体综合征,还能筛查其他非整倍体异常。由于母血清产前筛查只是一种筛查试验,仍存在一些假阴性或假阳性病例,应做好产前筛查结果的遗传咨询和产前诊断等后续工作。展开更多
文摘In this study, the immuno-response of recombinant hCG-β and natural hCGβ was comparatively investigated by using Freund's adjuvant. The results showed that, the properties and merits of the antibodies elicited by both kinds of hCG-β were similar. The antisera had high affinity for binding with hCG (Kαγβ≈5.86×108/mol/L, Kαβ≈8.18×108/mol/L), and were found to be effective in inhibiting the binding of 125I-hCG to receptors in rat testes. Results also indicated that, similar to the antisera induced by natural hCG-β, the recombinant hCG-β induced antisera had capacity of neutralizing the biological activities of hCG. Recombinant hCG-β could be used as an immunogen for contraceptive vaccine.
